Read by QxMD icon Read

Prostate Cancer Screening Test

Mahmoud A Alfaqih, Emma H Allott, Robert J Hamilton, Michael R Freeman, Stephen J Freedland
An increasing amount of data supports an inverse association between statin use and cancer risk. The findings for prostate cancer, particularly advanced disease, are the most promising of all cancers studied. Use of these agents seems to also be associated with improved prostate- cancer-specific survival, particularly in men undergoing radiotherapy, suggesting usefulness of statins in secondary and tertiary prevention. Some study results might be influenced by increased PSA screening and health-conscious behaviour in statin users but these factors are unlikely to completely account for observed beneficial effects...
October 25, 2016: Nature Reviews. Urology
Britton Trabert, Ronald C Eldridge, Ruth M Pfeiffer, Meredith S Shiels, Troy J Kemp, Chantal Guillemette, Patricia Hartge, Mark E Sherman, Louise A Brinton, Amanda Black, Anil K Chaturvedi, Allan Hildesheim, Sonja I Berndt, Mahboobeh Safaeian, Ligia Pinto, Nicolas Wentzensen
Inflammation is proposed to increase risk of developing endometrial cancer, but few prospective epidemiologic studies have investigated the relationship between circulating inflammation markers and endometrial cancer risk. In a nested case-control study within the PLCO Screening Trial we measured serum levels of 64 inflammation-related biomarkers in 284 incident endometrial cancer cases and 284 matched controls. Using multivariable logistic regression inflammation markers were evaluated individually and combined into a cross-validated inflammation score...
October 22, 2016: International Journal of Cancer. Journal International du Cancer
Majid Barati, Mohammad Ali Amirzargar, Saeed Bashirian, Vahid Kafami, Amir Abbas Mousali, Babak Moeini
BACKGROUND: Prostate cancer is the fourth most common cancer worldwide and is the second most lethal cancer. OBJECTIVES: The aim of this study was to investigate psychological predictors of prostate cancer screening behaviors among men over 50 years of age in Hamadan. MATERIALS AND METHODS: This cross-sectional study was carried out on 200 men over 50 years of age in Hamadan, west of Iran. Participants were recruited with a cluster sampling method...
August 2016: Iranian Journal of Cancer Prevention
Thais Caldara Mussi, Yves Bohrer Costa, Marcos Takeo Obara, Marcos Roberto Gomes de Queiroz, Rodrigo Gobbo Garcia, José Antonio Domingos Cianciarulo Longo, Gustavo Caserta Lemos, Ronaldo Hueb Baroni
Objective: To describe the imaging findings of prostatic tumors nonadenocarcinoma on multiparametric magnetic resonance imaging. Methods: A total of 200 patients underwented multiparametric magnetic resonance imaging of the prostate for screening for prostate cancer, from August 2013 to September 2014, followed by biopsy with ultrasound/magnetic resonance imaging fusion. Results: We found three pathologic proved cases of prostatic pure leiomyomas (0...
July 2016: Einstein
Simon B Zeichner, Christine Stanislaw, Jane L Meisel
In recent years, we have learned a great deal about pathogenic mutations that increase the risk of breast and ovarian cancer, particularly mutations in the BRCA1 and BRCA2 genes. Here we review current guidelines on breast and ovarian cancer screening, prophylactic surgery, and other risk-reduction strategies in patients with these mutations, and we detail the data that drive these recommendations. We also discuss guidelines on screening and management for other cancers associated with BRCA1 and BRCA2, such as male breast cancer, pancreatic cancer, and prostate cancer...
October 15, 2016: Oncology (Williston Park, NY)
Kosei Nakajima, Lance K Heilbrun, Daryn Smith, Victor Hogan, Avraham Raz, Elisabeth Heath
The U.S. Preventive Services Task Force (USPSTF) has recommended against PSA-based screening for prostate cancer due to potential possibilities of false-results. Since no alternative test is available to replace it, we have initiated a trial with the purpose of establishing whether Galectin-3 (Gal-3) serum level and/or the patients' immune response to PSA and Gal-3 antigens could complement the PSA test as diagnostic tools for prostate cancer patients. A blind, prospective, single institution, pilot study was conducted...
October 12, 2016: Oncotarget
Eleanor I Walsh, Emma L Turner, J Athene Lane, Jenny L Donovan, David E Neal, Freddie C Hamdy, Richard M Martin
BACKGROUND: Sociodemographic characteristics are associated with participating in cancer screening and trials. We compared the characteristics of those responding with those not responding to a single invitation for prostate-specific antigen (PSA) testing for prostate cancer as part of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP). METHODS: Age, rurality and deprivation among 197,763 men from 271 cluster-randomised primary care centres in the UK were compared between those responding (n = 90,300) and those not responding (n = 100,953) to a prostate cancer testing invitation...
October 13, 2016: Trials
Colin Thomas, Yingbiao Ji, Niraj Lodhi, Elena Kotova, Aaron Dan Pinnola, Konstantin Golovine, Peter Makhov, Kate Pechenkina, Vladimir Kolenko, Alexei V Tulin
The clinical potential of PARP-1 inhibitors has been recognized >10years ago, prompting intensive research on their pharmacological application in several branches of medicine, particularly in oncology. However, natural or acquired resistance of tumors to known PARP-1 inhibitors poses a serious problem for their clinical implementation. Present study aims to reignite clinical interest to PARP-1 inhibitors by introducing a new method of identifying highly potent inhibitors and presenting the largest known collection of structurally diverse inhibitors...
October 4, 2016: EBioMedicine
Azza Shoaibi, Gowtham A Rao, Bo Cai, John Rawl, Kathlyn Sue Haddock, James R Hébert
PURPOSE: To investigate if a prostate specific antigen (PSA)-derived growth curve can predict the occurrence of high-risk prostate cancer (PrCA). METHODS: Data from 38,340 men randomized to the PrCA screening arm in the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO) were used to develop a PSA growth curve model to estimate PSA rate of change. The model was then used to predict high-risk PrCA in clinical data available from 680,390 veterans seeking routine care...
October 4, 2016: Prostate
Ya-Lan Wu, Yong-Mei Liu, Hui-Jiao Chen, Yong-Sheng Wang, You Lu
Ureteral urothelial carcinoma (UC) is a rare malignant tumor. The most common clinical manifestations of ureteral UC are hematuria, increased urinary frequency, dysuria and pain. The diagnosis of ureteral UC is made via radiography, endoscopy and pathology. Although osteoblastic destruction is usually observed in metastasis of prostate cancer, UC can also be a reason for osteoblastic metastasis. The present study reports the case of a 66-year-old man presenting with osteoblastic metastases, in which the primary tumor was finally diagnosed as a ureteral UC...
October 2016: Oncology Letters
Corey H Basch, Anthony Menafro, Jennifer Mongiovi, Grace Clarke Hillyer, Charles E Basch
In the United States, prostate cancer is the most common type of cancer in men after skin cancer. There is a paucity of research devoted to the types of prostate cancer information available on social media outlets. YouTube™ is a widely used video sharing website, which is emerging as commonplace for information related to health. The purpose of this study was to describe the most widely viewed YouTube™ videos related to prostate cancer. The 100 videos were watched a total of 50,278,770 times. The majority of videos were uploaded by consumers (45...
September 29, 2016: American Journal of Men's Health
Abdul Malik Tun Firzara, Chirk Jenn Ng
OBJECTIVE: Screening for prostate cancer remains controversial. General practitioners (GPs) play an important role in assisting men to make an informed decision on prostate cancer screening. The aim of this study was to determine the knowledge and practice of prostate cancer screening among private GPs in Malaysia. DESIGN: A cross-sectional study. SETTING: Private general practices in Selangor, Malaysia. PARTICIPANTS: 311 randomly selected full-time private GPs were recruited between September 2013 and January 2014...
2016: BMJ Open
Zeinab Almasi, Abdollah Mohammadian-Hafshejani, Hamid Salehiniya
PURPOSE: No comprehensive study of cancer incidence and mortality exists in Iran. This study aimed to evaluate the incidence, mortality and epidemiological aspects of cancers in our country. METHODS: In this study, information of cancer incidence and mortality in Iran was retrieved from International Cancer Registry data and reported by numbers, crude and standardized incidence and mortality rates. Cancer incidence and mortality in Iran were mapped and compared with neighboring countries and the world...
July 2016: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
Andrew J Knighton, Tom Belnap, Kim Brunisholz, Kelly Huynh, Jay T Bishoff
INTRODUCTION: The introduction of the protein-specific antigen (PSA) test in care means that prostate cancer (PCa) is being detected earlier and more frequently. The result of increased screening using PSA, digital rectal examination and awareness of prostate was an increase in the number of men with low risk cancers. Active surveillance has become a viable alternative to immediate treatment with surgery, radiation and other forms of localized treatment. Evidence suggests that there is no significant difference in mortality rates between AS and surgery...
2016: EGEMS
Elizabeth M Whitley, Peter C Raich, Donald J Dudley, Karen M Freund, Electra D Paskett, Steven R Patierno, Melissa Simon, Victoria Warren-Mears, Frederick R Snyder
BACKGROUND: Whether patient navigation improves outcomes for patients with comorbidities is unknown. The aims of this study were to determine the effect of comorbidities on the time to diagnostic resolution after an abnormal cancer screening test and to examine whether patient navigation improves the timeliness and likelihood of diagnostic resolution for patients with comorbidities in comparison with no navigation. METHODS: A secondary analysis of comorbidity data collected by Patient Navigation Research Program sites using the Charlson Comorbidity Index (CCI) was conducted...
September 20, 2016: Cancer
Wendy Yi Xu, Jeah Kyoungrae Jung
OBJECTIVE: Consuming low-value health care not only highlights inefficient resource use but also brings an important concern regarding the economics of disparities. We identify the relation of socioeconomic characteristics to the use of low-value cancer screenings in Medicare fee-for-service (FFS) settings, and quantify the amount subsidized from nonusers and taxpayers to users of these screenings. DATA SOURCES: 2007-2013 Medicare Current Beneficiary Survey, Medicare FFS claims, and the Area Health Resource Files...
September 13, 2016: Health Services Research
Vivian Colón-López, Ana P Ortiz, Naydi Pérez, Eliseo Acevedo, Vivian Tamayo, Carmen D Zorrilla
OBJECTIVE: Due to advances in the care of people living with HIV/AIDS (PLWHA), life expectancy significantly increased, putting this group vulnerable to age-related comorbidities, such as cancer. The objective of this study was to describe the knowledge of cancer screening (cervical, breast, anal, colon, prostate) and other cancer prevention strategies (HPV vaccination, HPV testing) among HIV care professionals in Puerto Rico (PR). METHODS: Cross-sectional study using a sample of 104 HIV healthcare professionals in PR...
September 2016: Puerto Rico Health Sciences Journal
Nigel P Murray, Sócrates Aedo, Eduardo Reyes, Cynthia Fuentealba, Omar Jacob
INTRODUCTION: Around 90% of prostate cancers detected using the serum prostate specific antigen (PSA) as a screening test are considered to be localised. However, 20-30% of men treated by radical prostatectomy experience biochemical failure within two years of treatment. The presence of primary circulating prostate cells (CPCs) in the blood of these men implies a dissemination of the tumour and could indicate a greater risk of treatment failure. OBJECTIVE: To evaluate the use of the number of primary CPCs detected before surgery in the prediction of biochemical failure at ten years...
2016: Ecancermedicalscience
Dorthe Skovgaard, Morten Persson, Malene Brandt-Larsen, Camilla Christensen, Jacob Madsen, Thomas Levin Klausen, Soeren Holm, Flemming Littrup Andersen, Annika Loft, Anne Kiil Berthelsen, Helle Pappot, Klaus Brasso, Niels Kroman, Liselotte Hoejgaard, Andreas Kjaer
INTRODUCTION: Overexpression of urokinase-type plasminogen activator receptors (uPAR) represents an established biomarker for aggressiveness in most common malignant diseases, including breast (BC), prostate (PC) and urinary bladder cancer (UBC) and is therefore an important target for new cancer therapeutic and diagnostic strategies. In the study, uPAR Positron Emission Tomography (PET) imaging using a (68)Ga-labelled version of the uPAR targeting peptide (AE105) was investigated in a group of patients with BC, PC and UBC...
September 8, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Ashley T Fancher, Yun Hua, Daniel P Camarco, David A Close, Christopher J Strock, Paul A Johnston
The continued activation of androgen receptor (AR) transcription and elevated expression of AR and transcriptional intermediary factor 2 (TIF2) coactivator observed in prostate cancer (CaP) recurrence and the development of castration-resistant CaP (CRPC) support a screening strategy for small-molecule inhibitors of AR-TIF2 protein-protein interactions (PPIs) to find new drug candidates. Small molecules can elicit tissue selective effects, because the cells of distinct tissues express different levels and cohorts of coregulatory proteins...
October 2016: Assay and Drug Development Technologies
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"